Attached files
| file | filename |
|---|---|
| EX-99.1 - PAVmed Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 25, 2018
PAVMED INC.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-37685 | 47-1214177 | ||
| (State or Other Jurisdiction | (Commission | (IRS Employer | ||
| of Incorporation) | File Number) | Identification No.) |
One Grand Central Place, Suite 4600, New York, NY 10165
(Address of Principal Executive Offices) (Zip Code)
(212) 949-4319
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
| Item 8.01. | Other Events. |
On January 25, 2018, PAVmed Inc. (the “Company”) issued a press release announcing the closing of the sale of 234,540 shares (the “Option Shares”) of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriter in the Company’s previously announced public offering of 2,415,278 shares of common stock (the “Firm Shares”). The Firm Shares and Option Shares were sold to the public for a price of $1.80 per share. The Firm Shares and the Option Shares were sold pursuant to an underwriting agreement dated January 19, 2018, by and between the Company and Dawson James Securities, Inc., as the sole underwriter.
The sale of the Firm Shares and Option Shares generated total net proceeds, after underwriting discounts and payment of other offering expenses, of approximately $4.3 million.
The press release announcing the consummation of the sale of the Option Shares is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statement and Exhibits. |
| (d) | Exhibits: |
| Exhibit | Description |
| 99.1 | Press Release dated January 25, 2018. |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 25, 2018
| PAVMED INC. | ||
| By: | /s/ Lishan Aklog, M.D. | |
| Name: | Lishan Aklog, M.D. | |
| Title: | Chief Executive Officer | |
| 3 |